Production (Stage)
Cognition Therapeutics, Inc.
CGTX
$0.3225
$0.02428.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -15.78% | -28.42% | -0.16% | -6.60% | 0.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.32% | -29.40% | -1.91% | 24.21% | 57.16% |
| Operating Income | 2.32% | 29.40% | 1.91% | -24.21% | -57.16% |
| Income Before Tax | 7.33% | 3.67% | -47.24% | -48.98% | -48.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 7.33% | 3.67% | -47.24% | -48.98% | -48.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.33% | 3.67% | -47.24% | -48.98% | -48.27% |
| EBIT | 2.32% | 29.40% | 1.91% | -24.21% | -57.16% |
| EBITDA | 2.32% | 29.46% | 1.93% | -24.23% | -57.23% |
| EPS Basic | 49.43% | 33.12% | -10.62% | -10.09% | -27.91% |
| Normalized Basic EPS | 49.44% | 31.46% | -10.66% | -10.13% | -27.83% |
| EPS Diluted | 48.40% | 34.01% | -12.46% | -12.50% | -27.91% |
| Normalized Diluted EPS | 49.44% | 31.46% | -10.66% | -10.13% | -27.83% |
| Average Basic Shares Outstanding | 83.27% | 44.00% | 33.11% | 35.28% | 15.95% |
| Average Diluted Shares Outstanding | 83.27% | 44.00% | 33.11% | 35.28% | 15.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |